两天内,已有4家国内上市药企官宣了4笔对外授权交易,涉及ADC、双抗、CAR-T疗法、等热门赛道。 10月17日早间,翰森制药集团有限公司 (翰森制药,3692.HK)公告称,已与罗氏就HS-20110签署许可协议,翰森制药授予罗氏在全球范围内(不含中国内地、香港、澳门和台湾)推进HS-20110开发及商业化的独家权益。根据协议,翰森制药将获得8000万美元首付款,并有资格根据该产品开发、注册...
Source Link两天内,已有4家国内上市药企官宣了4笔对外授权交易,涉及ADC、双抗、CAR-T疗法、等热门赛道。 10月17日早间,翰森制药集团有限公司 (翰森制药,3692.HK)公告称,已与罗氏就HS-20110签署许可协议,翰森制药授予罗氏在全球范围内(不含中国内地、香港、澳门和台湾)推进HS-20110开发及商业化的独家权益。根据协议,翰森制药将获得8000万美元首付款,并有资格根据该产品开发、注册...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.